MYC and cholangiocarcinoma: It was noteworthy that Peraldo-Neia [14] recently showed, in preclinical cell models of cholangiocarcinoma, that trabectedin is able to inhibit the Wnt/β-catenin pathway, leading to downregulation of MYCC expression, proliferation inhibition, and apoptosis enhancement.